Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Viscum Album Stem, derived from European Mistletoe, is a complex botanical extract used primarily in complementary oncology and homeopathic medicine for its immunomodulatory and cytotoxic properties.
Name
Viscum Album Stem
Raw Name
VISCUM ALBUM STEM
Category
Other
Drug Count
4
Variant Count
4
Last Verified
February 17, 2026
About Viscum Album Stem
Viscum Album Stem, derived from European Mistletoe, is a complex botanical extract used primarily in complementary oncology and homeopathic medicine for its immunomodulatory and cytotoxic properties.
Detailed information about Viscum Album Stem
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Viscum Album Stem.
According to the National Cancer Institute (NCI, 2024), mistletoe extracts are among the most widely studied complementary and alternative medicine (CAM) therapies for cancer in Europe. In the United States, however, the Food and Drug Administration (FDA) has not approved Viscum Album Stem as a prescription drug for the treatment of cancer or any other medical condition. It is often available as a homeopathic remedy or administered under Investigational New Drug (IND) protocols in clinical trials. The drug class for Viscum Album Stem is generally categorized under 'Antineoplastic Phytotherapeutic Agents' or 'Immunostimulants.'
The pharmacological activity of Viscum Album Stem is attributed to its complex mixture of biologically active macromolecules, primarily mistletoe lectins (ML I, II, and III), viscotoxins, polysaccharides, and triterpene acids. The mechanism of action is multi-faceted, involving both direct cytotoxic effects and indirect immunomodulatory responses.
At the molecular level, mistletoe lectins are Type II ribosome-inactivating proteins (RIPs). They consist of an A-chain and a B-chain. The B-chain binds to galactose or N-acetylgalactosamine residues on the surface of target cells, facilitating the entry of the A-chain into the cytoplasm. Once inside, the A-chain inhibits protein synthesis by removing a specific adenine residue from the 28S ribosomal RNA, leading to cell cycle arrest and the induction of apoptosis (programmed cell death). This cytotoxic action is particularly observed in rapidly dividing malignant cells.
Simultaneously, Viscum Album Stem acts as a potent immunostimulant. It triggers the release of various cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These signaling molecules activate natural killer (NK) cells, macrophages, and T-lymphocytes, enhancing the body's innate surveillance against tumor cells. Studies published in the Journal of Experimental & Clinical Cancer Research (2023) suggest that these extracts also help stabilize DNA in healthy white blood cells, potentially protecting them from the damaging effects of cytotoxic chemotherapy.
Understanding the pharmacokinetics of a complex botanical extract like Viscum Album Stem is challenging because it contains hundreds of individual components. However, clinical focus is usually placed on the mistletoe lectins.
In jurisdictions where it is regulated (such as Germany and Switzerland), Viscum Album Stem is indicated for:
Viscum Album Stem is available in several specialized formulations, often named based on the host tree from which the mistletoe was harvested (e.g., Viscum album mali from apple trees, Viscum album pini from pine trees, Viscum album quercus from oak trees). Common forms include:
> Important: Only your healthcare provider can determine if Viscum Album Stem is right for your specific condition. In the United States, mistletoe is not an FDA-approved treatment for cancer.
Dosage for Viscum Album Stem is highly individualized and depends on the patient's condition, the stage of the disease, and the specific brand of extract used (e.g., Iscador, Helixor, Abnoba-viscum). There is no universal 'standard' dose, but clinical protocols typically follow a 'rhythmic' or 'induction' phase.
Healthcare providers usually begin with a very low dose, such as 0.01 mg or 0.1 mg, administered subcutaneously two to three times per week. The goal is to induce a controlled local skin reaction (redness and swelling) at the injection site, ideally between 10 mm and 20 mm in diameter.
If the initial dose is well-tolerated, the concentration is gradually increased until the desired immunological response is achieved. Maintenance doses often range from 1 mg to 20 mg per injection. Some protocols involve 'series' packs where the concentration varies over several weeks to prevent the body from becoming desensitized to the extract.
Viscum Album Stem is not routinely recommended for pediatric use due to a lack of robust safety and efficacy data in children. However, in some European countries, it may be prescribed by specialized pediatric oncologists in very specific cases. In such instances, the dose is strictly calculated based on the child's body surface area and monitored closely for hypersensitivity. Always consult a pediatric specialist before considering this treatment for a minor.
Because the metabolic fragments of mistletoe proteins are excreted by the kidneys, patients with severe renal impairment (CrCl < 30 mL/min) should be monitored closely. While specific dose reductions are not standardized, a slower titration schedule is often advised.
There are no specific guidelines for hepatic impairment. However, since mistletoe lectins can stimulate the liver's immune cells (Kupffer cells), patients with active hepatitis or liver cirrhosis should use Viscum Album Stem with extreme caution.
Elderly patients may have a more sluggish immune response. Healthcare providers may start at the lowest possible dose and increase it more slowly than in younger adults to monitor for systemic side effects like fever or fatigue.
If you miss a dose, take it as soon as you remember, provided it is not the same day as your next scheduled dose. If you are close to your next dose, skip the missed one and resume your regular schedule. Do not double the dose to catch up. Frequent missed doses may require you to restart the titration at a lower concentration to avoid an over-reactive immune response.
An overdose of Viscum Album Stem primarily results in an exaggerated immune response. Symptoms may include:
In case of a suspected overdose, discontinue the injections immediately and contact your doctor. Treatment is generally supportive, including hydration and antipyretics (like acetaminophen) to manage fever.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
The most common side effects of Viscum Album Stem are actually considered 'intended' signs of the drug's activity on the immune system. These include:
> Warning: Stop taking Viscum Album Stem and call your doctor immediately if you experience any of these.
With prolonged use (months to years), some patients may develop:
There are currently no FDA Black Box Warnings for Viscum Album Stem, largely because it is not an FDA-approved drug for cancer treatment. However, European regulatory bodies emphasize the risk of anaphylaxis in patients with known hypersensitivity to mistletoe proteins.
Report any unusual symptoms to your healthcare provider. Clinical data from the Cochrane Database of Systematic Reviews (2019) indicates that while mistletoe is generally well-tolerated, its safety profile depends heavily on correct administration and dose titration.
Viscum Album Stem is a potent biological substance and must be handled with care. It should only be used under the supervision of a healthcare professional experienced in mistletoe therapy. Patients must be aware that while mistletoe is 'natural,' it contains toxic proteins (viscotoxins and lectins) that can cause significant systemic reactions if used improperly.
No FDA black box warnings for Viscum Album Stem. However, users should be aware that the FDA has not evaluated the safety or efficacy of mistletoe for cancer treatment. Using mistletoe as a substitute for standard, evidence-based cancer treatments (like surgery, chemotherapy, or radiation) can lead to serious harm or death.
Patients undergoing Viscum Album Stem therapy should have regular check-ups including:
Viscum Album Stem generally does not cause drowsiness. However, if a patient experiences a 'mistletoe fever' or flu-like symptoms after an injection, their ability to concentrate or react quickly may be impaired. It is advised to avoid driving or operating heavy machinery until you know how the medication affects you, particularly during the first few weeks of therapy.
There are no known direct chemical interactions between Viscum Album Stem and alcohol. However, alcohol can interfere with the body's immune response and may worsen the inflammatory side effects (like headache or fatigue) caused by the mistletoe extract. It is generally recommended to limit alcohol consumption during active therapy.
Viscum Album Stem does not cause physical dependence, so there is no 'withdrawal syndrome.' However, stopping the drug suddenly may result in a decline in the perceived quality-of-life benefits. If you need to stop the medication, consult your doctor. If therapy is paused for more than two weeks, you may need to restart at a lower dose to avoid an over-reactive immune response when resuming.
> Important: Discuss all your medical conditions with your healthcare provider before starting Viscum Album Stem.
Viscum Album Stem should not be used concurrently with:
For each major interaction, the mechanism is usually pharmacodynamic (opposing or additive effects on the immune system) rather than pharmacokinetic (interference with liver enzymes). The clinical consequence is typically either reduced efficacy of the mistletoe or an exaggerated inflammatory response. Management involves careful timing of doses and frequent clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Viscum Album Stem must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
There is no well-documented cross-sensitivity between Viscum Album Stem and common drugs like penicillin or sulfa. However, patients who are highly sensitive to other members of the Santalales order of plants should be monitored closely for allergic reactions.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Viscum Album Stem.
Viscum Album Stem is generally not recommended during pregnancy. There is a lack of adequate and well-controlled studies in pregnant women. Animal studies have shown that high doses of mistletoe lectins may have embryotoxic effects. Furthermore, the induction of fever (a common side effect) can be hazardous during the first trimester, potentially increasing the risk of neural tube defects. If a patient becomes pregnant while on mistletoe therapy, the medication should typically be discontinued immediately unless there is a compelling medical reason to continue, which must be discussed with a high-risk obstetrician.
It is unknown whether the components of Viscum Album Stem, such as mistletoe lectins, are excreted in human milk. Because many proteins are degraded in the infant's digestive tract, the risk might be low, but the potential for allergic sensitization in the nursing infant cannot be ruled out. Due to the lack of safety data, breastfeeding is generally discouraged while using therapeutic mistletoe extracts.
As previously noted, Viscum Album Stem is not FDA-approved for use in children. While some specialized clinics in Europe use it for pediatric oncology, this is considered highly experimental. Children have a more 'reactive' immune system, and the risk of high fever and severe local reactions is greater than in adults. It is not approved for treating common childhood conditions like ADHD, autism, or routine infections.
In patients over age 65, Viscum Album Stem is generally well-tolerated, but the immune response may be less vigorous. Geriatric patients are at a higher risk for polypharmacy; therefore, a thorough review of their medication list for potential immunosuppressants or cardiovascular drugs is essential. There is no evidence that mistletoe increases the risk of falls, but if it causes significant flu-like symptoms, elderly patients should be monitored for dehydration.
Patients with impaired kidney function (GFR < 60 mL/min/1.73m²) do not typically require a specific dose reduction, but they should be monitored for signs of systemic toxicity. The large proteins in Viscum Album Stem are not cleared by dialysis; therefore, the timing of the injection relative to dialysis sessions is not critical, but the patient's overall inflammatory state must be considered.
For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), no specific dose adjustments are provided in the literature. However, for those with severe liver failure or acute hepatitis, the drug should be avoided due to the potential for the immune system to further damage liver tissue.
> Important: Special populations require individualized medical assessment.
Viscum Album Stem exerts its effects through two primary pathways: Apoptosis Induction and Immunomodulation.
The onset of the immunological effect (e.g., cytokine release) occurs within hours of injection. The 'local reaction' at the injection site typically peaks at 24–48 hours. The duration of effect on the immune system can last for 3–4 days, which is why a schedule of 2–3 injections per week is standard. There is no evidence of traditional 'tolerance' to the cytotoxic effects, but the immune system's inflammatory response may diminish over time, requiring a change in the extract's host-tree source.
| Parameter | Value |
|---|---|
| Bioavailability | < 1% (Oral); High (Subcutaneous) |
| Protein Binding | Primarily binds to glycoproteins/glycolipids |
| Half-life | 2–12 hours (Lectin components) |
| Tmax | 1–4 hours (Subcutaneous) |
| Metabolism | Proteolytic degradation (Non-CYP) |
| Excretion | Renal (as peptide fragments) |
Viscum Album Stem extracts are aqueous or fermented solutions containing:
Viscum Album Stem belongs to the class of Botanical Antineoplastic Agents. It is distinct from traditional chemotherapy because it does not directly interfere with DNA replication but rather induces apoptosis and stimulates the host's own immune defenses.
Medications containing this ingredient
Common questions about Viscum Album Stem
Viscum Album Stem, or European Mistletoe, is primarily used as a supportive and complementary therapy for patients undergoing cancer treatment. It is intended to improve quality of life by reducing symptoms like cancer-related fatigue, nausea, and emotional distress. In some European medical traditions, it is also used to stimulate the immune system and support the body’s natural defenses against malignant cells. It is important to note that it is not considered a primary cure for cancer and is typically used alongside conventional treatments like surgery or chemotherapy. Always consult with an oncologist before adding mistletoe to a treatment plan.
The most frequent side effects include localized reactions at the injection site, such as redness, swelling, and mild itching, which are often seen as signs that the immune system is responding. Patients may also experience a mild increase in body temperature, sometimes referred to as 'mistletoe fever,' and occasional flu-like symptoms such as headache or fatigue. These reactions are usually temporary and tend to resolve within a day or two. However, if the skin reaction exceeds two inches in diameter or if a high fever develops, you should contact your healthcare provider immediately. Rare but serious allergic reactions, including anaphylaxis, can occur in sensitive individuals.
There is no known direct chemical interaction between alcohol and the active components of Viscum Album Stem. However, alcohol can cause inflammation and may worsen some of the side effects of mistletoe therapy, such as headaches or fatigue. Furthermore, alcohol can suppress certain aspects of the immune system, which might counteract the intended immunostimulating effects of the mistletoe extract. Most healthcare providers recommend avoiding or significantly limiting alcohol consumption to ensure the body is in the best possible state to respond to therapy. Always discuss your lifestyle habits with your doctor during treatment.
Viscum Album Stem is generally not recommended for use during pregnancy due to a lack of comprehensive safety data in humans. Some animal studies have suggested that high doses of mistletoe components could potentially interfere with fetal development or have embryotoxic effects. Additionally, the fever that often accompanies mistletoe injections could be risky for the developing fetus, particularly in the first trimester. Because the risks are not fully understood, most medical guidelines advise against starting or continuing mistletoe therapy while pregnant. If you are pregnant or planning to become pregnant, you must inform your healthcare provider before using this product.
The time it takes to see results from Viscum Album Stem can vary depending on the goal of treatment. Immunological changes, such as an increase in certain white blood cells, can often be detected in blood tests within a few weeks of starting therapy. Improvements in quality of life, such as increased energy levels or better appetite, are typically reported after 4 to 8 weeks of consistent use. However, the 'local reaction' at the injection site usually happens within 24 hours of the very first dose. Because it is a supportive therapy, its effects are often gradual and cumulative rather than immediate.
Stopping Viscum Album Stem suddenly does not cause a traditional withdrawal syndrome because the drug is not addictive and does not affect the central nervous system in that way. However, if the therapy was providing benefits for energy levels or immune support, those benefits may gradually fade after discontinuation. If you have been taking mistletoe for a long time and stop for more than two weeks, you should not resume at your previous high dose without consulting your doctor. Your body may have lost its 'habituation' to the extract, and restarting at a high dose could cause an excessively strong immune reaction or high fever.
If you miss a scheduled injection of Viscum Album Stem, you should take it as soon as you remember, as long as it is not the same day as your next scheduled dose. If you are very close to your next injection, simply skip the missed one and continue with your regular schedule. Do not administer two doses at once to make up for the one you missed, as this could lead to an over-stimulation of the immune system and a high fever. If you miss several doses in a row, contact your healthcare provider, as they may want you to temporarily lower your dose when you restart.
Viscum Album Stem is not typically associated with unexplained weight gain. In fact, many patients in palliative care settings use mistletoe to help improve their appetite and maintain a healthy weight while fighting cancer. If you experience sudden or unusual weight gain while taking this medication, it is more likely related to other factors, such as changes in your primary cancer treatment, fluid retention, or dietary changes. Always report significant changes in weight to your medical team to ensure they are properly evaluated. It does not have the metabolic side effects common with steroid medications.
Viscum Album Stem can interact with other medications, particularly those that affect the immune system. It should be used with caution if you are taking immunosuppressants, such as corticosteroids or drugs used to prevent organ transplant rejection, as mistletoe may reduce their effectiveness. There is also limited data on how mistletoe interacts with modern immunotherapy drugs (checkpoint inhibitors), so close monitoring by an oncologist is required. Most other medications, like those for blood pressure or cholesterol, do not have known interactions with mistletoe. Always provide your doctor with a full list of all prescriptions and supplements you are taking.
Viscum Album Stem is a complex botanical extract rather than a simple chemical molecule, so the concept of a 'generic' version is slightly different than for drugs like ibuprofen. Instead, there are several different brands and manufacturers that produce mistletoe extracts, such as Iscador, Helixor, and Abnoba. Each of these brands may use different host trees (like apple, oak, or pine) and different extraction methods, meaning they are not exactly identical. In the United States, these products are not FDA-approved as 'generic' or 'brand-name' drugs for cancer and are usually obtained through specialized pharmacies or as homeopathic preparations.